Investigation of the possibility of using ischemia-modified albumin as a novel and early prognostic marker in cardiac arrest patients after cardiopulmonary resuscitation.
Кључне речи
Апстрактан
BACKGROUND
Early and accurate prediction of survival to hospital discharge following resuscitation after cardiac arrest (CA) is a major challenge. Our aim was to investigate the levels of ischemia-modified albumin (IMA) and malondialdehyde (MDA) in CA patients and whether IMA levels are valuable early marker of post-cardiopulmonary resuscitation prognosis in CA patients.
METHODS
We enrolled 52 in- or out-of-hospital CA patients, with 47 healthy volunteers as the control group (CG). Blood samples were taken for IMA and MDA measurement at the beginning or within 5 min of commencement of CPR. The patients were classified according to the Glasgow Outcome Score (GOS) into a poor outcome group (POG) and a good outcome group (GOG).
RESULTS
Mean IMA levels were higher in POG (0.25+/-0.07 ABSU) than in GOG (0.19+/-0.07 ABSU, p=0.002) and also than CG (0.16+/-0.04 ABSU, p=0.0001). The IMA levels were not significantly higher in GOG than in CG (p=0.32). The mean MDA levels in POG (0.77+/-0.27 nmol/ml) were comparable to the levels in GOG (0.75+/-0.18 nmol/ml, p>0.05), but were significantly higher than in CG (0.60+/-0.15 nmol/ml, p=0.001). MDA levels were not significantly higher in GOG than in CG (p=0.06). The optimum cut-off point for IMA maximizing sensitivity and specificity was 0.235 ABSU, with sensitivity of 65.8% and specificity of 78.6%. The corresponding +PV and -PV were 85.3% and 45.8%, respectively.
CONCLUSIONS
In conclusion, though the result may not be applied clinically in every patient, the ischemia-modified albumin may be a valuable prognostic marker in cardiac arrest patients following CPR.